Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2004-08-03
2011-12-13
Peng, Bo (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S005000, C424S184100, C424S188100
Reexamination Certificate
active
08076060
ABSTRACT:
This invention provides a method whereby a vaccine, particularly a vaccine based on a prophylactic or therapeutic AIDS/HIV vaccine, or other immune-reactive substance is administered to produce an immunologic response that decreases intraocular pressure or has a neuro-protective effect beneficial in the treatment of glaucoma patients. The invention may also be used as a provocative test to diagnose glaucoma as well as identify those patients at risk for developing glaucoma. The invention may also be used to prevent the development of glaucoma in patients deemed to be at high risk of developing glaucoma, such as glaucoma suspects or ocular hypertensive patients.
REFERENCES:
patent: 4952581 (1990-08-01), Bito et al.
patent: 5334394 (1994-08-01), Kossovsky et al.
patent: 5516796 (1996-05-01), Stjernschantz et al.
patent: 5658569 (1997-08-01), Osther et al.
patent: 5741492 (1998-04-01), Hurwitz et al.
patent: 5741810 (1998-04-01), Burk
patent: 5763160 (1998-06-01), Wang
patent: 5846546 (1998-12-01), Hurwitz et al.
patent: 5861243 (1999-01-01), Dietrich et al.
patent: 5928930 (1999-07-01), Salk et al.
patent: 5981276 (1999-11-01), Sodroski et al.
patent: 6017543 (2000-01-01), Salk et al.
patent: 6090392 (2000-07-01), Berman
patent: 6096902 (2000-08-01), Burk
patent: 6218428 (2001-04-01), Chynn
patent: 6331404 (2001-12-01), Berman et al.
patent: 6350467 (2002-02-01), Demopoulos et al.
Russell ND et al. “Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial.” J Acquir Immune Defic Syndr. Feb. 1, 2007;44(2):203-12.
Jones NG, et al. “AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection.” Vaccine. Dec. 9, 2008[Epub ahead of print] pp. 1-5.
Tezel G, Wax MB. “Glaucoma” Chem Immunol Allergy. 2007;92:221-7. Review.
Wax MB.“Is there a role for the immune system in glaucomatous optic neuropathy?” Curr Opin Ophthalmol. Apr. 2000;11(2):145-50. Review.
Vecino E “Animal models in the study of glaucoma: past, present and future” ARCH SOC ESP OFTALMOL 2008; 83: 517-520.
Galatt, Kirk “Animal models for glaucoma” Invest. Ophthalmol. Visual Sci. 16(7):592-596; 1977.
Mermoud A. et al. “Animal model for uveitic glaucoma” Grafe's Arch Clin Exp Ophthalmol. 232:553-560; 1994.
Letvin N. et al. “Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination” Proc. Natl. Acad. Sci. USA vol. 94, pp. 9378-9383, Aug. 1997.
Arevalo JF, et al, “Correlation between intraocular pressure and CD4+ T-lymphocyte counts in patients with human immunodeficiency virus with and without cytomegalovirus retinitis”, Am J Ophthalmol, 122(1): 91-6 (1996).
Cartwright et al., “Immune-related disease and normal-tension glaucoma: a case-control study”, Arch Ophthalmol, 110(4): 500-2 (1992).
Fineman et al., “Bilateral choroidal effusions and angle-closure glaucoma associated with human immunodeficiency virus infection”, Retina, 17(5): 455-7 (1997).
Haynes et al., “The Current Status of HIV-1 Vaccine Development 2004”, Resources section of the National Institute of Allergy and Infectious Disease (NIAID) website www.niaid.nih.gov, pp. 1-32 (2004).
Johnston et al., “Progress in HIV vaccine development”, Current Opinion in Pharmacol, 1:504-510 (2001).
Kipnis et al., “T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies”, Proc Natl Acad Sci USA, Jun 20: 97(13): 7446-51 (2000).
Loewen et al., “Genetic modification of human trabecular meshwork with lentiviral vectors”, Hum Gene Ther, 12(17): 2109-19 (2001).
Nagasubramanian et al., “Immunological investigations in chronic simple glaucoma”, Trans Ophthalmol Soc UK, 98(1): 22-7 (1978).
Nash et al., “Bilateral angle-closure glaucoma associated with uveal effusion: presenting sign of HIV infection”, Surv Ophthalmol, 36(4): 255-8 (1992).
Polansky et al., “Cellular Mechanisms Influencing the Aqueous Outflow Pathway”, Principles and Practice of Ophthalmology, Albert et al. Eds., pp. 226-251 (1994).
Schori et al., “Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: implications for glaucoma”, Proc Natl Acad Sci USA, 98(6): 3398-403 (2001).
Schwartz et al., “Potential treatment modalities for glaucomatous neuropathy: neuroprotection and neuroregeneration”, J Glaucoma (Dec; 5(6): 427-32 (1996).
The Jordan Report 20thAnniversary Accelerated Development of Vaccines 2002: Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Disease, National Institutes of Health (2002).
Ullman et al., “Bilateral angle-closure glaucoma in association with the acquired immune deficiency syndrome”, American Journal of Ophthalmol, 101(4): 419-24 (1986).
Wax, “Is there a role for the immune system in glaucomatous optic neuropathy?”, Curr Opin Ophthalmol, 11(2): 145-50 (2000).
Zambarakji et al., “Bilateral angle closure glaucoma in HIV infection”, J R Soc Med, 89 (10): 581-2 (1996).
Zegans et al., “Transient vitreous inflammatory reactions associated witih combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis”, Am J Ophthalmol, 125(3): 292-300 (1998).
Pimentel et al., “Secondary Acute Angle Closure Glaucoma: A Complication of AIDS”, Jour. of Emergency Medicine, vol. 15, No. 6, pp. 811-814 (1997).
Fellman et al., “Effects of Methotrexate Treatment on Serum Immunoreactivity of a Patient with Normal-Pressure Glaucoma”, Amer. Journ. of Ophthalmology, vol. 127, No. 6, pp. 724-725 (1999).
Yang et al., “T Cell Subsets and sIL-2R/IL-2 Levels in Patients with Glaucoma”, Amer. Journ. of Ophthalmology, vol. 131, No. 4, pp. 421-426 (2001).
McDonald James S.
Peng Bo
LandOfFree
Vaccination and immunotherapy as new therapeutic modalities... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccination and immunotherapy as new therapeutic modalities..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccination and immunotherapy as new therapeutic modalities... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4315428